SCHEMBL23096828

SCHEMBL23096828

CC(=O)N1CCN(C(=O)CCC=O)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ MEN1 O00255 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ PIK3CD O00329 1/20 0.41
▸ GLA P06280 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5857321 0.84 KMT2A (0.45) TDP1CYP1A2MEN1KMT2AALDH1A1
SCHEMBL5530068 0.81 ATM (0.60) TDP1MEN1KMT2AALDH1A1KDM4E
SCHEMBL3498067 0.79 ATM (0.58) TDP1CYP1A2MEN1KMT2AALDH1A1
SCHEMBL6499575 0.79 TDP1 (0.48) TDP1CYP1A2MEN1KMT2AALDH1A1
SCHEMBL8185942 0.79 CYP1A2 (0.48) TDP1CYP1A2MEN1KMT2AALDH1A1
SCHEMBL12457130 0.77 TDP1 (0.50) TDP1CYP1A2MEN1KMT2AALDH1A1
SCHEMBL7142593 0.77 CYP1A2 (0.38) TDP1CYP1A2MEN1KMT2AALDH1A1
SCHEMBL3950507 0.76 PIK3CD (0.50) TDP1CYP1A2ALDH1A1KDM4EPIK3CD
SCHEMBL12443868 0.76 DDB1 (0.44) TDP1MEN1KMT2AALDH1A1KDM4E
SCHEMBL4816120 0.76 L3MBTL1 (0.52) ALDH1A1LMNAUSP2HSD17B10GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11560401-B2 Method for preparing oligonucleic acid compound NIPPON SHINYAKU CO., LTD. (JP) 2023-01-24 — — US disclosed
US-20230014840-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND NIPPON SHINYAKU CO., LTD. (JP) 2023-01-19 — — US disclosed
US-20230018780-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND NIPPON SHINYAKU CO., LTD. (JP) 2023-01-19 — — US disclosed
EP-3792269-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND Nippon Shinyaku Co., Ltd. (JP) 2021-03-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230018780-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND POLRMT, POLR2H, POLM TDP1 96/4885CYP1A2 4633/4885MEN1 2008/4885
US-11560401-B2 Method for preparing oligonucleic acid compound POLRMT, POLI, POLR2H TDP1 278/4885CYP1A2 4524/4885MEN1 1485/4885
US-20230014840-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND DNASE1, XRN2, FBL TDP1 65/4885CYP1A2 2387/4885MEN1 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback